Outlook Therapeutics requests Type A meeting with FDA following second CRL for ONS-5010 | Optometry Times - Clinical News & Expert Optometrist Insights

Published on September 22, 2025
Outlook Therapeutics seeks FDA clarity on ONS-5010 after a complete response letter, aiming to address efficacy concerns for wet AMD treatment.
Continue reading on website
Other news

Northern Ireland to reinstate automatic access to free sight tests for most Universal Credit recipients

September 22, 2025
The development, which is set to take effect in October, will see Northern Ireland reach parity with the rest of the UK

Psoriasis Linked to Increased Risk of Multiple Ocular Disorders

September 23, 2025
Patients with psoriasis face significantly increased risks for several ocular conditions, according to a new meta-analysis involving over 10 million individuals, published in AJO. The study found up to a fivefold increase in dry eye disease and elevated risks for cataract, uveitis, glaucoma and other eye disorders. The study authors emphasize the need for interdisciplinary care and routine ocular